JOHNSON & JOHNSON — Form 8-K
Filed October 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Johnson & Johnson reported Q3 2026 sales of $25.4B (5.9% growth) and raised full-year 2026 guidance to $101.2B (7.4% midpoint growth) and adjusted EPS to $11.10 (2.9% increase). The quarter was marked by a $5.5B pre-tax litigation charge for proposed talc settlement, the completed acquisition of Firefly Bio (amount undisclosed), and a collaboration with Sail Biomedicines on CAR-T programs. Adjusted EPS of $2.59 reflected these charges; underlying operational growth was solid across Innovative Medicine (7.9%) and MedTech (2.5%).
Why this rating
Guidance raise and strong ops offset by one-time talc charge ($5.5B ≈ 1.5% of market cap). Routine quarterly beat with M&A activity immaterial relative to $367B scale.
See more from October 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.